ArticleJournal of cutaneous medicine and surgery
Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab.
Article in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of adalimumab treatment on lesions and inflammatory factors in patients with moderate-severe hidradenitis suppurativa.American journal of translational research · 2026Article
- Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.Journal of cutaneous medicine and surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdalimumab is a biologic used in the treatment of hidradenitis suppurativa (HS). Therapeutic drug monitoring (TDM) has emerged as a potential strategy to optimize treatment efficacy, yet its utility in HS remains underexplored. Our aim was to assess the utility of TDM in HS patients with suboptimal adalimumab response by investigating the prevalence of antidrug antibodies and subtherapeutic drug levels.
methodsA cross-sectional study of 62 patients with suboptimal response to adalimumab was conducted at a dermatology clinic in Toronto, Ontario. Data on adalimumab serum trough levels, autoantibody status, and demographics were collected. Patients were divided into therapeutic (≥10.6 μg/mL) and subtherapeutic (<10.6 μg/mL) drug categories based on trough level.
resultsOf 51 patients on adalimumab 40 mg weekly, 32 patients (62.7%) had therapeutic drug levels and 19 (37.3%) had subtherapeutic levels. In the 11 patients on adalimumab 80 mg weekly, 7 patients had therapeutic drug levels (28.19 μg/mL) and 4 had subtherapeutic levels (mean 3.26 μg/mL). Autoantibodies were detected in 21.06% of patients with subtherapeutic drug levels on adalimumab 40 mg weekly. There was a significant association between Hurley stage and drug level (
conclusionsIn HS patients with suboptimal response to standard adalimumab dosing, a significant number of patients have subtherapeutic drug levels with a minority of those having anti-adalimumab antibodies. TDM can be helpful in identifying HS patients with subtherapeutic drug levels and without antidrug antibodies who could potentially benefit from dose escalation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.